Clareo Health | Trials

Back to your record

Login Get started

Finding studies

1–20 of 5,132

RecruitingElectrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any HistotypeThis is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing…NCT06753136Padova CompletedVeliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyThis phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy.NCT00892736Duarte, California and 6 others RecruitingPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma PatientsThis is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma…NCT06730009Tainan Active not recruitingAn Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) AdenocarcinomaThe purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately…NCT04837833New York, New York RecruitingAtebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaThe purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.NCT07562152Huntsville, Alabama and 75 others CompletedFOLFIRINOX Plus IPI-926 for Advanced Pancreatic AdenocarcinomaThe purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin)…NCT01383538San Francisco, California and 2 others CompletedVaccine Study for Surgically Resected Pancreatic CancerTo assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.NCT00569387Scottsdale, Arizona and 17 others CompletedComparison of Prognosis Between Open Pancreatic Surgery With Vein Resection and Reconstruction Versus Minimally Invasive Pancreatic Surgery With Vein Resection and Reconstruction for Pancreatic CancerThe prognostic differences between open and minimally invasive radical pancreatic surgery combined with venous resection and reconstruction remain controversial, and there is a…NCT07414004Xi'an, Shaanxi CompletedCetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by SurgeryRATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.NCT00599833Leeds, England and 1 other CompletedEUS-guided Ablation of Pancreatic Cyst NeoplasmsThis is a registry that will maintain prospective data on the clinical outcomes of all patients with pancreatic cyst lesions who undergo EUS-guided alcohol ablation.NCT02422147Orlando, Florida RecruitingCollection of Circulating Biomarkers in Pancreatic CancerThis protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.NCT05743049Philadelphia, Pennsylvania WithdrawnBinimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerThis early phase I trial studies the direct effects on cancer cells of the drugs binimetinib and palbociclib, in patients with KRAS-positive lung, colorectal, or pancreatic cancer…NCT04870034Buffalo, New York TerminatedSafety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic…NCT00364364Baltimore, Maryland RecruitingDostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIThe goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for…NCT06333314Angers and 21 others CompletedPostoperative Oral Nutritional Supplementation After Major Gastrointestinal SurgeryPatients who underwent major gastrointestinal surgery is potentially at risk of malnutrition due to reduced oral intake, increased nutritional need, reduced gastrointestinal…NCT01838109Seoul CompletedSafety and Feasibility Study of Enhanced Recovery in PancreaticoduodenectomyThe purpose of this study is to assess the adherence to an enhanced recovery after surgery (ERAS) pathway and the impact of the ERAS protocol on postoperative short-term outcome…NCT01759706Milan, MI Not yet recruitingExocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes PathophysiologyThe EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic…NCT07670871 RecruitingPhase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic CarcinomaRR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer.NCT06861452Modena, Italy CompletedCetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerRATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.NCT00448838Miami, Florida RecruitingEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerThis study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and…NCT03579836Seoul

Data from ClinicalTrials.govTerms